|
|
Article: Publication No. WO/2009/133101 Published on Nov. 5, Assigned to Novartis for Fibroblast Growth Factor Receptor Kinase Activity Modulation Monitoring Method, Usage (Swiss, British Inventors)
- Article from:
- US Fed News Service, Including US State News
- Article date:
- November 9, 2009
CopyrightCopyright © HT Media Ltd. All Rights Reserved. Provided by ProQuest LLC. (Hide copyright information)
|
GENEVA, Nov. 11 -- Diana Graus porta, Vito Guagnano and Estelle Marrer, all from Switzerland, and Pablo Verdes, Great Britain, have developed a methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods.
The patent has been assigned to Novartis AG, Basel, Switzerland.
According to an abstract posted by the World Intellectual Property Organization: "The present invention relates generally to methods of in vitro diagnostics, in particular the use of a compound selected from the group consisting of fibroblast growth factor 23, inorganic phosphorus, the product of inorganic phosphorus and total calcium, osteopontin and parathyroid ...